Bender Robert & Associates Uro Gen Pharma Ltd. Transaction History
Bender Robert & Associates
- $414 Million
- Q4 2024
A detailed history of Bender Robert & Associates transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Bender Robert & Associates holds 34,701 shares of URGN stock, worth $365,748. This represents 0.09% of its overall portfolio holdings.
Number of Shares
34,701Holding current value
$365,748% of portfolio
0.09%Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
134Shares Held
36.3MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.83MShares$40.4 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$39.4 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.3 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$23 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $240M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...